Gaithersburg, Maryland, United States
• 18+ years in industrial Biologics Discovery and Pre-clinical Development • Leader of high-performing teams of up to 19 FTE in antibody discovery programs from target proposal to pre-clinical upstream development • Experience working in multi-disciplinary matrix across sites and countries (EU/US) • Proven track record in Biologics Discovery for complex modalities in Immunology/Oncology (T/NK-engager, ADC, sdAb, multi-specifics) • Strategic leader with a focus on driving technology innovation and collaboration • Strong passion for streamlining processes and knowledge management within Biologics discovery • Effectively managed external partnerships and strategic alliances with industry and academic partners to onboard cutting edge technologies • Goal-oriented mindset to accelerate the advancement of promising drugs into the clinic
• Leading a group responsible for discovery, NGS sequencing, functional and epitope characterization of antibody lead candidates across BMS disease areas (oncology, I/O, cell therapy) • Build functional HT assay capabilities and integrated biosensor group to enable efficient ‘function-first’ lead selection • Strategic management of internal/external resources; CRO management • Management of external alliances to access technologies for tumor-localized activation concepts (T-/NK-engagers, ADCs, tissue-targeting multi-specifics) • Contribution to early discovery portfolio strategy
• Team leader (17 FTE) responsible for delivering functional sequence and epitope diversified hit sets for >50 therapeutics and tool antibody programs per year in close collaboration with Biology teams across all BMS sites. • Transformed team and technologies from Hybridoma towards broader platform approach including Single B-cell; phage display and immune repertoire sequencing • Discovery project co-lead of oncology and immune-oncology programs • Leading cross-discipline/site strategic initiatives (implementation of discovery database (GDB), cross-site technology off-site, building HT screening and functional assay capabilities, people strategy).
Leading a group responsible for production of hit and lead candidates of in NBE Discovery: - Managing a team of 11 full-time employees - Responsible to lead V-gene recovery from Single B-Cell and hybridoma campaigns, molecular biology and expression/purification of hits and leads from mammalian cell culture - Co-leader of global biotherapeutic projects in Discovery - Key interface liaison to clinical manufacturing units in Germany & Austria - Experience with various therapeutic molecule formats (IgGs, fusion proteins, VHHs, multi-specifics) - Collaboration with inter-disciplinary teams across sites, strategic partners and CROs
Leading the Expression Group responsible for the production of lead proteins from mammalian and microbial systems: - Managing a team of 7 full-time employees - Co-leader of global biotherapeutic projects in Discovery - Evaluation and implementation of new production technologies - Experience with various therapeutic molecule formats (IgGs, fusion proteins, VHHs, bi-specifics) - Collaboration with inter-disciplinary teams across sites, strategic partners and CROs
Management of new technology development programs in a matrix function: - Coordination of external collaborations with academic and industrial partners - Global strategic alignment of technology programs - Leading inter-disciplinary initiatives